NERV Strangle Strategy
NERV (Minerva Neurosciences, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Minerva Neurosciences, Inc. functions as a biopharmaceutical firm in the clinical development stage, primarily dedicated to uncovering and bringing to market novel therapeutic options for disorders affecting the central nervous system. Its portfolio of experimental treatments notably features roluperidone, an investigational drug aimed at managing schizophrenia, alongside MIN-301, a soluble recombinant variant of the neuregulin-1b1 protein, which is being explored for its potential in treating Parkinson's disease and various other neurodegenerative conditions. The company has a contractual licensing agreement with Mitsubishi Tanabe Pharma Corporation, authorizing the worldwide development, distribution, and import of roluperidone, with the explicit exclusion of the Asian continent. Established in 2007, this organization initially operated as Cyrenaic Pharmaceuticals, Inc. before undergoing a name change to Minerva Neurosciences, Inc. in 2013. Its corporate headquarters are located in Waltham, Massachusetts.
NERV (Minerva Neurosciences, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $182.6M, a beta of -0.11 versus the broader market, a 52-week range of 1.76-12.46, average daily share volume of 210K, a public-listing history dating back to 2014, approximately 7 full-time employees. These structural characteristics shape how NERV stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of -0.11 indicates NERV has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a strangle on NERV?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
NERV snapshot
As of August 14, 2026, spot at $4.56, ATM IV 20.80%, IV rank 4.11%, expected move 5.96%. The strangle on NERV below is built from the end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this strangle structure on NERV specifically: NERV IV at 20.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a NERV strangle, with a market-implied 1-standard-deviation move of approximately 5.96% (roughly $0.27 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated NERV expiries trade a higher absolute premium for lower per-day decay. Position sizing on NERV should anchor to the underlying notional of $4.56 per share and to the trader's directional view on NERV stock.
NERV strangle setup
The NERV strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With NERV at $4.56 on that close, the first option leg uses a $4.79 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed NERV chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 NERV shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $4.79 | N/A |
| Buy 1 | Put | $4.33 | N/A |
NERV strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
NERV strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on NERV. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on NERV
Strangles on NERV are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the NERV chain.
NERV thesis for this strangle
The market-implied 1-standard-deviation range for NERV extends from approximately $4.29 on the downside to $4.83 on the upside. A NERV long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current NERV IV rank near 4.11% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on NERV at 20.80%. As a Healthcare name, NERV options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to NERV-specific events.
NERV strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. NERV positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move NERV alongside the broader basket even when NERV-specific fundamentals are unchanged. Always rebuild the position from current NERV chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on NERV?
- A strangle on NERV is the strangle strategy applied to NERV (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With NERV stock at $4.56 on the most recent close, the strikes shown on this page are snapped to the nearest listed NERV chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are NERV strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the NERV strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 20.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a NERV strangle?
- The breakeven for the NERV strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from the end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The NERV market-implied 1-standard-deviation expected move in the same options snapshot is approximately 5.96%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on NERV?
- Strangles on NERV are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the NERV chain.
- How does current NERV implied volatility affect this strangle?
- NERV ATM IV is at 20.80% with IV rank near 4.11%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.